Unusually large paraganglioma complicated with successive catecholamine crises: A case report and review of the literature

Zhenhui Huang, Guojian Liang, Hua Shen, Chuyuan Hong, Xuexia Yin and Shi Zhang*

Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Background: Paragangliomas are rare neuroendocrine tumors that could secret catecholamines. Hypertension and heart failure caused by the catecholamine crisis are fatal cardiovascular events. However, silent paragangliomas that lack typical symptoms of catecholamine pose a significant diagnostic challenge.

Case summary: A 45-year-old woman who presented with more than 1-year history of abdominal discomfort was suspected of having a gastrointestinal stromal tumor by a local hospital since a vast metastatic mass occupied her left abdomen. Thus, she was recommended to our hospital. After completing the gastroscopy, she unexpectedly developed acute heart failure and was transferred to the Intensive Care Unit (ICU) where the initial diagnosis of paraganglioma was considered through path. However, a second catecholamine crisis due to constipation led to acute heart failure again. After anti-heart failure therapy and rigorous preoperative preparation, surgery was arranged to remove the tumor. Postoperative pathology confirmed the paraganglioma, and the patient was discharged from the hospital in good condition.

Conclusion: We reported a rare case of huge retro-peritoneal paraganglioma with successive catecholamine crises and acute heart failure. This was probably the largest retro-peritoneal paraganglioma since the 1980s. Besides, we were the first to use surgical drawing to illustrate its complex anatomical adjacent relationship of retroperitoneal tumor. Our case emphasizes the inclusion of extra-adrenal paraganglioma in the differential diagnosis of retroperitoneal tumors. In suspected paragangliomas, catecholamine testing is preferable to invasive procedures including gastroscopy and biopsy to avoid triggering a catecholamine crisis. Surgical resection is the primary treatment. We highlight the priority of dealing with the venous reflux branches of the tumor to prevent the release of catecholamines into the blood. In particular, preoperative preparation plays a vital role in managing paraganglioma. Moreover, it is necessary to schedule genetic testing and clinical follow-up due to the metastatic potential of paragangliomas.

KEYWORDS
paraganglioma, extra-adrenal pheochromocytoma, catecholamine crisis, acute heart failure, neuroendocrine tumor, retro-peritoneal tumor
Introduction

Paragangliomas are rare neuroendocrine tumors arising from chromaffin cells of the parasympathetic or sympathetic paraganglia outside of the adrenal glands (1). Clinical symptoms include hypertension, tachycardia, headache, sweating, etc. The intermittent nature of these symptoms often leads to a delay in the diagnosis (2). Paraganglioma can cause catecholamines cardiomyopathy including myocardial infarction, heart failure, and arrhythmia (2). Catecholamine crisis is an uncommon and dreaded complication.

Herein, we described a rare and severe case of huge paraganglioma with two times catecholamine crises to underline the diagnosis and treatment of silent paragangliomas that lack typical manifestations.

Case presentation

A 45-year-old woman was admitted to our hospital in February 2021, who presented with acid reflux in the past one month followed by more than a one-year history of abdominal discomfort after eating. She had normal menstruation without a history of hypertension, coronary heart disease, diabetes, or other diseases. There was no family history of illness. Suspected to be a gastrointestinal stromal tumor by the local hospital due to a vast mass occupying her abdomen through abdominal computed tomography (CT), she was recommended to our hospital for further diagnosis and treatment.

Vital signs on presentation were blood pressure=120/60 mmHg, heart rate=82 beats/min, and respiratory rate=20 times/min. On examination, the left abdominal mass was palpable with poor activity and unclear border. In addition, there is no tenderness and rebound pain in the abdomen. Moreover, all laboratory tests including blood routine, liver function, coagulation function, biochemistry even tumor markers did not show significant abnormalities.

However, after finishing the gastroscopy, she felt sudden pain and discomfort under the xiphoid accompanied by sweating, chest tightness, and shortness of breath that night. On examination, her heart rate was 110–127 beats/min, and respiratory rate was 20–24 times/min, and her blood pressure fluctuated from 117–179/78–91 mmHg (the maximum blood pressure was 179/91 mmHg), with blood oxygen was 90%–100% and her both lungs had no obvious rales on auscultation.

A series of emergent measures were taken immediately. Subsequently, laboratory tests revealed a significant increase in biochemical markers of myocardial injury, including type B natriuretic peptide pro-N-terminal (6980.00 ng/L, normal range 0–125 ng/L), cardiac troponin (15.60 μg/L, normal range 0–0.03 μg/L), myoglobin (291.7 μg/L, normal range 0–106 μg/L), alanine transaminase (177.00 U/L, normal range 13–14 U/L), lactate dehydrogenase (1015.00 U/L, normal range 120–246 U/L), creatine kinase (933.20 U/L, normal range 40–200 U/L), and creatine kinase isoenzyme (147.70 U/L, normal range 0–25 U/L). The inflammatory markers were much higher than normal, such as the level of white blood cell count [22.62 × 109/L, normal range (4–10) × 109/L], and neutrophil ratio (90.60%, normal range 40%–75%). Then, we asked the cardiologist for urgent consultation, and he considered differential diagnoses, including acute myocardial infarction and acute heart failure. Due to the rapid heart rate and the progressive decline in blood oxygen, the patient was transferred to ICU for further monitoring and treatment.

The echocardiography in ICU showed moderate systolic dysfunction with the left ventricular ejection fraction of 35%. However, the coronary angiography did not see any sign of myocardial infarction. Furthermore, the thoracic CT showed considerable exudative lesions in both lungs. Meanwhile, abdominal CT (Figures 1A,B) revealed that a vast space-occupying lesion was located in her left middle and upper abdomen and its blood supply mainly came from the inferior mesenteric artery (IMA). The imaging suggested that this may be paraganglioma, but it should differentiate from the mesenchymal malignant tumor such as liposarcoma and fibrosarcoma. Until then, we did not realize the possibility of paraganglioma.

Later, the laboratory test associated with paraganglioma was arranged. The result revealed a significant increase in both urine catecholamine and Plasma catecholamine (Table 1, ICU 1st time). Consequently, the diagnosis was considered to be paraganglioma.

With her physical condition markedly improved, she was transferred to our gastrointestinal surgery department for further treatment. However, she was pale, sweaty, and coughed up pink sputum due to constipation the next
day. Worse, she felt dyspneic as her degree of blood oxygen saturation decreased gradually. It was considered to be the result of the recurrence of acute left heart failure caused by the catecholamine crisis (Table 1, ICU 2nd time), so she was transferred to ICU again for advanced life support.

Since then, we recognized that the paraganglioma was easily stimulated to release catecholamines which could raise blood pressure and lead to acute heart failure. Imaginably, the next catecholamine crisis may be life-threatening. So, if the condition was permitted, we recommended that the surgery should be performed as early as possible, though the surgery was also a kind of stimulating factor.

After more than 1 month of anti-heart failure therapy and preparation, the surgery was performed under general anesthesia in April 2021. During the operation, we found that peritoneal giant mass with a volume of 17.0 cm × 13.1 cm × 10.7 cm was closely related to the peripheral blood vessels and organs (Figure 1C). Especially, the tumor had a common blood supply to the left half colon (Figures 1C,E). Together with the left hemicolon, the mass was separated carefully and removed entirely from the surrounding tissue (Figure 1F).

The catecholamine in both her urine and plasma returned to normal basically after surgery (Table 1). She developed the lymphatic leak latterly and was discharged from the hospital on the 23rd after surgery with good condition. Histological examination showed that the tumor measuring 17.0 cm × 13.1 cm × 10.7 cm, with an intact capsule had localized necrosis. It had invaded the mesentery of the colon as well as para-tumor lymph nodes. Immunohistochemistry showed CD56 (+), CgA (+), Syn (+), CK (−), CD34 (+), SMA (−), CD10 (−), EMA (−), HMB45 (−), Inhibin-α (−), MelanA (−), NF (−), S-100 (−), and the Ki-67 index was 15% (Figure 2). Based on morphology, immunohistochemistry, and clinical presentation, the tumor was finally confirmed as paraganglioma. The patient received genetic testing and no pathogenic genes were found.

Follow-up

After being followed up for 5 months, the patient was free of abdominal discomfort, sweating, acid reflux, or symptoms of heart failure. Meanwhile, there were no signs of recurrence through CT evaluation (Figure 3).

Discussion

Paragangliomas are unusual neuroendocrine neoplasms originating from cells derived from the neural crest. This tumor is called pheochromocytoma in the adrenal medulla and is known as extra-adrenal pheochromocytoma elsewhere or simply as paraganglioma (3). The incidence of pheochromocytoma and paraganglioma is about 0.6 cases per 100,000 person-years (4, 5).

Based on the presence or absence of typical clinical signs, retroperitoneal paragangliomas can be classified into three categories: non-functional, sub-clinical, and functional types. Patients with functional paragangliomas that overproduce catecholamines may experience the classic triad symptom
including tachycardia, headache, and diaphoresis (6–10). In contrast, those with non-functional retro-peritoneal paragangliomas are often diagnosed incidentally or manifest as compressive symptoms such as abdominal pain that may be associated with nausea, vomiting, abdominal distension, weight loss, or even paralytic ileus (8, 11, 12). Although the sub-clinical type of retro-peritoneal paraganglioma has the function of secreting catecholamines including epinephrine (E), norepinephrine (NE), and dopamine (DA), its secretion is too little to cause typical clinical symptoms and the blood pressure often fluctuates drastically as the stimulating factors trigger the release of catecholamines. This case is a sub-clinical retro-peritoneal paraganglioma. The patient was admitted to our hospital without hypertension, palpitations, diaphoresis, and other catecholamine-associated symptoms. But gastroscopy examination and constipation triggered successive catecholamine crises released from the paraganglioma, which resulted in strong arterial vasoconstriction with a sudden rise in blood pressure as well as coronary spasm that led to myocardial ischaemia and hypoxia. And this mechanism resulted in cardiomyopathy and other complications like acute left heart failure, cardiogenic pulmonary oedema, and pleural effusion. Therefore, it was difficult to diagnose this case due to the atypical clinical symptoms and severe complications. In differential diagnosis, paraganglioma located in the retro-peritoneum should be differentiated from nerve sheath tumor, liposarcoma, and giant lymph node hyperplasia. Diagnosis is made through laboratory and imaging tests (4). Consequently, metanephrines or their metabolites measurement in both plasma and urine is an excellent diagnostic method. It is recommended as an initial method of diagnosis according to the recommendations of clinical practice of the Society of Endocrinology (5). The ultrasound may be a first-line screening method. CT and MRI have higher sensitivity. Most retroperitoneal paragangliomas are round solid tumors with abundant blood supply, hemorrhagic cystic changes, and calcification. Functional imaging with meta-iodobenzylguanidine (MIBG) scintigraphy may be used for better localization of extra-adrenal disease or metastatic sites (11, 13). Although imaging techniques are helpful, the diagnosis of paragangliomas can only be confirmed with careful histological and immunohistochemical evaluation (14). The combination of immunohistochemical neuronal cell-specific enolase (NSE) and chromogranin (CgA) is up to 100% sensitive.

Paraganglioma with tumor size larger than 5 cm has a metastatic tendency. It is advisable to perform surgical resection to improve survival (15). Resection is often extremely risky since these highly vascular tumors are frequently located near multiple essential blood vessels. Preoperative preparation plays a vital role in the management of paraganglioma. After systematic treatments, the patient’s echocardiography result and the manifestation of heart failure were markedly improved. She took phenoxybenzamine and metolol for at least 14 days to normalize blood pressure and heart rate. Treatment also included fluid intake to reverse catecholamine-induced blood volume contraction preoperatively in case of severe hypotension after tumor removal. After that, the resection of the left retroperitoneal tumor was arranged to perform.

During the procedure, we found that the retro-peritoneal mass about 17 cm in diameter was adjacent to the peripheral vessels and organs like the abdominal aorta (AO), the left half colon, the middle colic artery (MCA), the inferior mesenteric artery (IMA), the left genitourinary system including the left side of kidney, ureter and renal vessels. Moreover, the tumor had a common blood supply with the left hemicolon (Figure 1C). In case of triggering the catecholamine crisis again by compression roughly, we adopted the open surgical excision through a median cross-cut incision and removed the tumor together with the left half of the colon gently. Of note, we prioritized ligation of tumor venous reflux branches to prevent catecholamines from being released into the blood, followed by the arterial branch of the tumor. In addition, it was essential to keep close collaboration with the anesthesiologist. Meanwhile, monitoring closely of cardiovascular and hemodynamic variables, including intro-arterial pressure and heart rhythm, was also required. Finally, the surgery was completed smoothly without significant complications. Operation time, blood loss, and volume of red blood transfused during the surgery were 210 min, 800 ml, and 6 units, respectively. The patient recovered from the operation after symptomatic treatment and had a good surgical outcome during follow-up. As tumors are said to be unresectable, attempts to reduce their size using chemotherapy,
radiation therapy, embolization or molecular-targeted therapy such as tyrosine kinase inhibitor may be indicated (16, 17).

A study showed that the 5-year likelihood of recurrence among those with an extra-adrenal paraganglioma was approximately 20% (18). Hence, patients should be followed up for life. We followed up with the patient 5 months later, and she was disease-free with a normal range of catecholamines in serum and urine, and no imaging evidence of recurrence had been found. It is reported that most cases of metastatic paragangliomas are associated with mutations or hereditary syndromes, such as mutations in rearranged during transfection (RET), neurofibromatosis type 1 (NF1), Von Hippel-Lindau (VHL), and gene mutations of the subunits of succinate dehydrogenase (SDH) (4, 19, 20). Given this condition, our patient had also undergone genetic testing, but the result did not see the above pathogenic genes.

Conclusion

We presented a rare case of retroperitoneal paraganglioma with successive catecholamine crises as well as acute heart failure. This is probably the largest retro-peritoneal paraganglioma since it was reported in the 1980s (7). Our case emphasizes the inclusion of extra-adrenal paraganglioma in the differential diagnosis of retroperitoneal tumors. In suspected paragangliomas, catecholamine testing is preferable to invasive procedures including gastroscopy and biopsy to avoid triggering a catecholamine crisis. Surgical resection is the mainstay of treatment. Surgical resection is the primary treatment. It is worth mentioning that we are the first to use surgical drawing to illustrate the complex anatomy of huge retroperitoneal paraganglioma. We highlight the priority of dealing with the venous reflux branches of the tumor to prevent the release of catecholamines into the blood. In particular, preoperative preparation plays a vital role in managing paraganglioma. Moreover, it is necessary to schedule genetic testing and clinical follow-up due to the metastatic potential of paragangliomas.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

ZH wrote the report and drew the postoperative surgical drawing. XY participated in perioperative management. SZ, GL, HS, and CH performed the surgery, and SZ performed the research and revised the report. All authors contributed to the article and approved the submitted version.

Funding

This report was supported by the Doctor Start-up Fund of the Second Affiliated Hospital of Guangzhou Medical University (NO.2016C18).

Acknowledgments

We thank Dr. Lei Chong (Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China) and Dr. Jiang Xiaofeng (the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China) for help with the revision.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Feng N, Zhang WY, Wu XT. Clinicopathological analysis of paraganglioma with literature review. World J Gastroenterol. (2009) 15:3003–8. doi: 10.3748/wjg.15.3003

2. Ma X, Chen Z, Xia P, Zhang C, Yan K, Fan Y, et al. Giant paraganglioma complicated with catecholamine crisis and catecholamine cardiomyopathy: a case report and review of the literature. Front Endocrinol. (2021) 12:790080. doi: 10.3389/fendo.2021.790080

3. Marchetto G, Attisani M, Rinaldi M, Pocar M. Left ventricular venting for extracorporeal life support in phaeochromocytoma. Perfusion. (2021) 36:103–4. doi: 10.1177/0267659120963930

4. Cerqueira A, Seco T, Costa A, Tavares M, Cotter J. Pheochromocytoma and paraganglioma: a review of diagnosis, management and treatment of rare causes of hypertension. Cureus. (2020) 12:e7969. doi: 10.7759/cureus.7969

5. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. (2014) 99:1915–42. doi: 10.1210/jc.2014-1498

6. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. (2001) 86:5210–6. doi: 10.1210/jcem.86.11.8034

7. Lack EE, Cubilla AL, Woodruff JM, Lieberman PH. Extra-adrenal paragangliomas of the retroperitoneum: a clinicopathologic study of 12 tumors. Am J Surg Pathol. (1980) 4:109–20. doi: 10.1097/00000478-198004000-00002

8. Matteucci M, Kowalowski M, Fina D, Jiritano F, Meani P, Raffa GM, et al. Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review. Perfus.ion. (2020) 35:20–8. doi: 10.1177/0267659120944000

9. Hayes WS, Davidson AJ, Grimley PM, Hartman DS. Extra-adrenal retroperitoneal paraganglioma: clinical, pathologic, and CT findings. AJR Am J Roentgenol. (1990) 155:1247–50. doi: 10.2214/ajr.155.6.2173385

10. Stojanowski S, Boldt HB, Kozic D, Patocs A, Korbonits M, Meda-Stojanowska M, et al. Case report: malignant primary sellar paraganglioma with unusual genetic and imaging features. Front Oncol. (2021) 11:739255. doi: 10.3389/fonc.2021.739255

11. Gannan E, van Veenendaal P, Scarlett A, Ng M. Retroperitoneal non-functioning paraganglioma: a difficult tumour to diagnose and treat. Int J Surg Case Rep. (2015) 17:133–5. doi: 10.1016/j.ijscr.2015.11.004

12. Kaltas G, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. (2004) 25:458–511. doi: 10.1210/er.2003-0014

13. van Gils AP, Falke TH, van Erkel AR, Arndt JW, Sandler MP, van der Mey AG, et al. MR imaging and MIBG scintigraphy of pheochromocytomas and extra-adrenal functioning paragangliomas. Radiographics. (1991) 11:37–57. doi: 10.1148/radiographics.11.1.1671719

14. Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol. (2005) 15:85–92. doi: 10.1007/s00330-004-2412-3

15. Ayala-Ramirez M, Feng L, Johnson MM, Eijaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. (2011) 96:717–25. doi: 10.1210/jc.2010-1946

16. Bryant RL, Stevenson DR, Hunton DW, Westbrook KC, Casali RE. Primary malignant retroperitoneal tumors. current management. Am J Surg. (1982) 144:646–9. doi: 10.1016/0002-9610(82)90543-8

17. O’Kane GM, Ezzat S, Joshua AM, Bourdeau L, Lebowitz-Amit R, Olney HJ, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. (2019) 120.1113–9. doi: 10.1038/s41416-019-0474-x

18. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Poisson FF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. (2005) 90:2110–6. doi: 10.1210/jc.2004-1398

19. Fushheim L. Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment. Hematol Oncol Clin North Am. (2016) 30:135–50. doi: 10.1016/j.hoc.2015.09.006

20. Neumann H, Young Jr WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. (2019) 381:552–65. doi: 10.1056/NEJMra1806651